Check out the on-demand educational recording from Africa Online Healthcare Week 2020 by clicking here. Dr Susanne Emmerich (Germany) discusses the relationship between diabetes and COVID-19, and how HbA1c point-of-care testing (POCT) impacts glycemic control in diabetic patients. Dr Carl Llor (Spain) discusses the value of C-reactive protein (CRP) POCT to aid assessment of COVID-19 and prevent unnecessary prescription of antibiotics.
View expert presentations on point-of-care testing for diabetes and in the context of COVID-19
Check out the on-demand symposium recording from the European Respiratory Society congress 2020 by clicking here. Learn how C-reactive protein (CRP) point-of-care testing can be a valuable diagnostic and clinical decision-making tool in relation to COVID-19, and how it may also inform antibiotic prescribing for acutely exacerbated chronic obstructive pulmonary disease (COPD) patients.
Learn about the value of CRP point-of-care testing for COPD and antimicrobial resistance in the context of COVID-19
An international expert panel discusses POCT related to COVID-19 severity assessment and risk prediction, plus covers the role of POCT in antimicrobial resistance during the pandemic, in this video seminar originally delivered live on 9 September 2020. Hear from Professor Nicholas Francis (UK), Professor Ivan Gentile (Italy), Dr Carl Llor (Spain), Professor Dag Berild (Norway) and Dr Aggy York (UK) by clicking here.
Hear expert opinion on the use of CRP point-of-care testing for COVID-19 management and reduction of antimicrobial resistance
An international expert panel discusses POCT related to COVID-19 severity assessment and risk prediction, plus covers the role of POCT in antimicrobial resistance during the pandemic, in this video seminar originally delivered live on 4 September 2020. Hear from Professor Nicholas Francis (UK), Professor Ivan Gentile (Italy), Dr Carl Llor (Spain), Professor Dag Berild (Norway) and Dr Aggy York (UK) by clicking here.
Hear expert opinion on the use of CRP POCT for COVID-19 management and reduction of antimicrobial resistance
The World Anti-Microbial Resistance (AMR) congress is the world’s largest AMR congress, with ~800 attendees from across ~50 countries and more than 250 speakers. This year, on 8–9 October 2020, myPOCacademy hosted a live seminar led by Professor Jonathan Cooke from Imperial College London and the University of Manchester (UK), now exclusively available to watch in full here.
Hear how point-of-care testing may aid in reducing antimicrobial resistance during the COVID-19 pandemic
Check out the on-demand educational recording from Africa Online Healthcare Week 2020 by clicking here. Dr Susanne Emmerich (Germany) discusses the relationship between diabetes and COVID-19, and how HbA1c point-of-care testing (POCT) impacts glycemic control in diabetic patients. Dr Carl Llor (Spain) discusses the value of C-reactive protein (CRP) POCT to aid assessment of COVID-19 and prevent unnecessary prescription of antibiotics.
View expert presentation on point-of-care testing for diabetes and in the context of COVID-19
The World Anti-Microbial Resistance (AMR) congress is the world’s largest AMR congress, with approximately 800 attendees from across approximately 50 countries and more than 250 speakers.
In our feature article series, we take a look at publications of particular relevance to point-of-care testing (POCT), providing summaries and expert commentary on the key aspects of the paper and within the wider context of POCT systems.
Point-of-care testing to improve cost-effectiveness of health check programmes in primary care
Cardiovascular diseases are a leading cause of death globally, taking 17.9 million lives each year1. Patients at risk of cardiovascular disease (CVD) may show raised blood pressure, have diabetes or have high lipid levels. The good news is, reducing the risk of cardiovascular disease (such as dyslipidemia, hypercholesterolemia and hypertriglyceridemia) is possible with lipid panel tests to identify risk, and continued testing for monitoring.
A one stop shop: the impact of point-of-care lipid testing on cardiovascular disease screening and management